Table 2.
Reported HER2 status in biopsies of primary tumours and metastases versus result of central pathology revision, and 89Zr-trastuzumab PET result
| Patient | Reported HER2 status | HER2 status after central revision | 89Zr-trastuzumab PET result |
|---|---|---|---|
| 1 | HER2+ and HER2- | HER2+ and HER2- | Positive |
| 2 | HER2+ | HER2+ | Positive |
| 3 | HER2+ and HER2- | HER2-a | Negative |
| 4 | HER2+ and HER2- | HER2+ and HER2- | Positive |
| 5 | HER2+ | HER2+ | Negativeb |
| 6 | HER2+ | HER2+ | Positive |
| 7 | HER2+ and HER2- | HER2+ and HER2- | Equivocal |
| 8 | HER2+ | HER2+ | Positive |
| 9 | HER2+ and HER2- | HER2+ and HER2- | Negative |
| 10 | HER2+ | HER2+ | Positive |
| 11 | HER2+ and HER2- | HER2+ and HER2- | Positive |
| 12 | HER2+ and HER2- | HER2+ and HER2- | Negative |
| 13 | HER2+ and HER2- | HER2+ and HER2- | Positive |
| 14 | HER2+ and HER2- | HER2-a | Negative |
| 15 | HER2+ | HER2+ | Positive |
| 16 | HER2+ | HER2+ | Positive |
| 17 | HER2+ and HER2- | HER2+ and HER2- | Negative |
| 18 | equivocal | HER2- | Negative |
| 19 | HER2+ | HER2+ and HER2-a | Positive |
| 20 | HER2+ | HER2+ | Positive |
aInitial HER2 IHC interpretation of primary tumour biopsy false positive
bLeptomeningeal metastases visualized on MRI where not visible on 89Zr-trastuzumab PET either due to negative HER2 status or due to their size below the detection limit